Scholarlink

Purpose <p>In nasopharyngeal carcinoma (NPC), the 12-week period following radiotherapy (RT) represents a critical surveillance window for detecting residual disease and distant metastasis. We aim to assess the role of PET/CT And cfEBV DNA levels at 12&#xa0;weeks post-RT in the surveillance of locoregionally advanced nasopharyngeal carcinoma (LA-NPC).</p> Methods <p>Patients with stage III-IVa LA-NPC were included. PET/CT scans were conducted both pre-treatment And at 12&#xa0;weeks post-RT. cfEBV DNA was assessed pre-treatment, at 4, 12, And 24&#xa0;weeks post-RT, And subsequently at 3- to 6-month intervals. The primary endpoint was the negative predictive value (NPV) of 12-week PET/CT for identifying locoregional residual disease (RD) and/or distant metastasis (DM).</p> Results <p>Between 2018 And 2021, 506 eligible patients were prospectively enrolled (median follow-up: 45.2&#xa0;months). At 12&#xa0;weeks post-RT, RD was identified in 22 patients (4.3%), DM in 30 patients (5.9%), And both RD And DM in 6 patients (1.2%). For overall RD and/or DM, 12-week PET/CT demonstrated An NPV of 96.3%, sensitivity of 72.4%, specificity of 93.3%, positive predictive value (PPV) of 58.3%, And accuracy of 90.9%. The corresponding values for 12-week cfEBV DNA were An NPV of 91.7%, sensitivity of 41.7%, specificity of 34.5%, PPV of 93.8%, And accuracy of 87.0%. Among subgroups defined by 12-week cfEBV DNA levels, patients with undetectable cfEBV DNA showed a 96.8% NPV for PET/CT, whereas those with detectable cfEBV DNA demonstrated an 85.0% sensitivity for PET/CT.</p> Conclusion <p>PET/CT performed at 12&#xa0;weeks post-RT is a reliable tool for surveillance in LA-NPC, facilitating the optimization of follow-up strategies and enabling timely therapeutic interventions. The combined use of PET/CT and cfEBV DNA provides valuable risk-stratified insights for managing patients effectively.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

[18F] Fluorodeoxyglucose positron emission tomography/computed tomography scan and liquid biopsy at 12 weeks posttreatment for surveillance of locoregionally advanced nasopharyngeal carcinoma

  • 期刊论文

  • 发表日期：

    2025年10月1日

查看全文
  • Li-Ting Liu,
  • Zhen-Chong Yang,
  • Jia-Rui He,
  • Hao-Xiang Long,
  • Ying-Ying Hu,
  • Jia-Yi Shen,
  • Mei-Juan Luo,
  • Yu-Chen Li,
  • Xu Zhang,
  • Su-Chen Li,
  • Zi-Jian Lu,
  • Bei-Bei Xiao,
  • Jin-Hao Yang,
  • Xiao-Fei Lv,
  • Yu-Jing Liang,
  • Shan-Shan Guo,
  • Sai-Lan Liu,
  • Xue-Song Sun,
  • Xiao-Yun Li,
  • Li Yuan,
  • Liang-Ji Li,
  • Guo-Dong Jia,
  • Xue-Bin Xie,
  • Kuok-Wai IU,
  • Wei Fan,
  • Qiu-Yan Chen,
  • Melvin L. K. Chua,
  • Hai-Qiang Mai,
  • Lin-Quan Tang

摘要

Purpose

In nasopharyngeal carcinoma (NPC), the 12-week period following radiotherapy (RT) represents a critical surveillance window for detecting residual disease and distant metastasis. We aim to assess the role of PET/CT And cfEBV DNA levels at 12 weeks post-RT in the surveillance of locoregionally advanced nasopharyngeal carcinoma (LA-NPC).

Methods

Patients with stage III-IVa LA-NPC were included. PET/CT scans were conducted both pre-treatment And at 12 weeks post-RT. cfEBV DNA was assessed pre-treatment, at 4, 12, And 24 weeks post-RT, And subsequently at 3- to 6-month intervals. The primary endpoint was the negative predictive value (NPV) of 12-week PET/CT for identifying locoregional residual disease (RD) and/or distant metastasis (DM).

Results

Between 2018 And 2021, 506 eligible patients were prospectively enrolled (median follow-up: 45.2 months). At 12 weeks post-RT, RD was identified in 22 patients (4.3%), DM in 30 patients (5.9%), And both RD And DM in 6 patients (1.2%). For overall RD and/or DM, 12-week PET/CT demonstrated An NPV of 96.3%, sensitivity of 72.4%, specificity of 93.3%, positive predictive value (PPV) of 58.3%, And accuracy of 90.9%. The corresponding values for 12-week cfEBV DNA were An NPV of 91.7%, sensitivity of 41.7%, specificity of 34.5%, PPV of 93.8%, And accuracy of 87.0%. Among subgroups defined by 12-week cfEBV DNA levels, patients with undetectable cfEBV DNA showed a 96.8% NPV for PET/CT, whereas those with detectable cfEBV DNA demonstrated an 85.0% sensitivity for PET/CT.

Conclusion

PET/CT performed at 12 weeks post-RT is a reliable tool for surveillance in LA-NPC, facilitating the optimization of follow-up strategies and enabling timely therapeutic interventions. The combined use of PET/CT and cfEBV DNA provides valuable risk-stratified insights for managing patients effectively.